The FDA has approved Noctiva (desmopressin acetate) nasal spray for frequent urination at night in adults due to overproduction of urine.
Indications: Noctiva is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.
Dosage/administration: Prime with 5 actuations before initial use if not use for more than 3 days.
- For patients aged <65 years who are not at increased risk for hyponatremia: Use 1 spray of 1.66 mcg in either nostril nightly approximately 30 minutes before going to bed.
- For patients ≥65 years or younger patients at risk for hyponatremia: Use 0.83 mcg nightly, which can be increased to one spray of 1.66 mcg after at least 7 days, if needed, provided the serum sodium has remained normal.
Adverse reactions: Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension/blood pressure increased, back pain, epistaxis, bronchitis and dizziness.
US Food and Drug Administration. FDA approves first treatment for frequent urination at night due to overproduction of urine. FDA Web site. March 3, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544877.htm. Accessed March 10, 2017.
This Week's Must Reads
Can Omega-3 Supplement Use Lower CVD Risk?, JAMA Cardiol; ePub 2018 Jan 31; Aung, et al
2018 Adult ACIP Immunization Schedule Released, Ann Intern Med; 2018 Feb 6; Kim, Riley, et al
2018 ACIP Immunization Schedule for Children, MMWR; ePub 2018 Feb 6; Robinson, et al
Weight Management & Remission of T2D in Primary Care, Lancet; 2018 Feb; Lean, Leslie, Barnes, et al
Prior Use of NOACs & Mortality in ICH Patients, JAMA; 2018 Feb 6; Inohara, Xian, Liang, et al
Must Reads in FDA Actions
FDA Approves Steglatro for Adults with T2D, Pfizer news release; 2017 Dec 22
FDA Approves Ozempic for Treatment of T2D, Novo Nordisk news release; 2017 Dec 5
FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20
FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14
Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23